Φορτώνει......
Targeting EZH2 methyltransferase activity in ARID1A mutated cancer cells is synthetic lethal
ARID1A, a chromatin remodeler, shows one of the highest mutation rates across many cancer types. Notably, ARID1A is mutated in over 50% of ovarian clear cell carcinomas, which currently has no effective therapy. To date, clinically applicable targeted cancer therapy based on ARID1A mutational status...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Nat Med |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2015
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4352133/ https://ncbi.nlm.nih.gov/pubmed/25686104 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.3799 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|